Sanofi Settles With Teva, Others Over Generic Eloxatin

Law360, New York (April 1, 2010, 5:40 PM EDT) -- Sanofi-Aventis SA has settled patent litigation against three drugmakers — Teva Pharmaceuticals Inc., Fresenius Kabi Pharmaceuticals Holding Inc. and Sandoz Inc. — over their plans to sell generic versions of cancer drug Eloxatin.

The deal, announced Thursday, resolves Sanofi's claims against the three in suits in the U.S. District Court for the District of New Jersey and the U.S. District Court for the District of Columbia, and will see generic versions of drug the pulled from the market within a few months.

The U.S. Food and...
To view the full article, register now.